Division of Nephrology, University of Alabama at Birmingham, USA.
Am J Physiol Renal Physiol. 2010 Oct;299(4):F732-9. doi: 10.1152/ajprenal.00293.2010. Epub 2010 Aug 4.
Epidemiological studies have established the role of cigarette smoking as a risk factor in the progression of chronic kidney disease, including diabetic nephropathy. We have previously reported that nicotine promotes mesangial cell proliferation and hypertrophy via activation of nonneuronal nicotinic acetylcholine receptors and that nicotine worsens renal injury in a model of acute glomerulonephritis (Jaimes E, Tian RX, Raij L. Am J Physiol Heart Circ Physiol 292: H76-H82, 2007; Jaimes EA, Tian RX, Joshi M, Raij L. Am J Nephrol 29: 319-326, 2009). These studies were designed to test the hypothesis that nicotine worsens renal injury in db/db mice, a well-established model of diabetic nephropathy, and that reactive oxygen species play an important as mediators of these effects. For these studies, nicotine (100 μg/ml) was administered in the drinking water to control and db/db mice for 10 wk. Blood pressure was measured by the tail-cuff method, and urine was collected for proteinuria. At death, kidneys were collected for histology and molecular biology. The administration of nicotine did not result in significant changes in blood pressure or blood glucose and resulted in cotinine levels similar to those found in the plasma of smokers. In diabetic mice, the administration of nicotine significantly increased urinary protein excretion (1-fold), glomerular hypertrophy, and mesangial area (∼20%). These changes were accompanied by significant increases in NADPH oxidase 4 (∼30%) and increased nitrotyrosine and Akt expression. In vitro, we determined that nicotine has additive effects to high glucose on reactive oxygen species generation and Akt phosphorylation in human mesangial cells. These findings unveil novel mechanisms that may result in the development of novel strategies in the treatment and prevention of diabetic nephropathy in smokers.
流行病学研究已经确定了吸烟作为慢性肾脏病(包括糖尿病肾病)进展的危险因素的作用。我们之前曾报道过,尼古丁通过激活非神经元烟碱型乙酰胆碱受体促进系膜细胞增殖和肥大,并且尼古丁在急性肾小球肾炎模型中加重肾脏损伤(Jaimes E、Tian RX、Raij L. Am J Physiol Heart Circ Physiol 292:H76-H82,2007;Jaimes EA、Tian RX、Joshi M、Raij L. Am J Nephrol 29:319-326,2009)。这些研究旨在检验以下假设:尼古丁在 db/db 小鼠(一种已建立的糖尿病肾病模型)中加重肾脏损伤,并且活性氧物质作为这些效应的重要介质发挥作用。对于这些研究,将尼古丁(100μg/ml)施用于对照和 db/db 小鼠的饮用水中 10 周。通过尾套法测量血压,并收集尿液用于蛋白尿。死亡时,收集肾脏进行组织学和分子生物学研究。尼古丁的给药未导致血压或血糖显著变化,并且导致可替宁水平与吸烟者的血浆中发现的水平相似。在糖尿病小鼠中,尼古丁的给药显著增加了尿蛋白排泄(增加 1 倍)、肾小球肥大和系膜区面积(增加约 20%)。这些变化伴随着 NADPH 氧化酶 4(增加约 30%)和硝基酪氨酸和 Akt 表达的显著增加。在体外,我们确定尼古丁对人系膜细胞中活性氧物质生成和 Akt 磷酸化有高葡萄糖的附加作用。这些发现揭示了可能导致在吸烟者中开发治疗和预防糖尿病肾病的新策略的新机制。